News

Findings from a survey of 363 clinical trial sites showing the profound effect of the coronavirus pandemic.

The latest FDA and EMA guidelines permit sites, sponsors, and CROs to adjust their operations to meet changing conditions for ongoing trials, including some concerning the safety of participants, that must be met in order for new solutions to be considered.

Biopharmaceutical sponsors should make urgent decisions now to plan for continued clinical research in the coming months.

Outlining the three concerns communicated the most when it comes to implementing an FSP outsourcing strategy.

Clinical research sites feel growing pressure to perform work in a compliant manner while keeping pace with stakeholder information exchange workstreams, but lack the consistent processes to do so.